Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Liabilities

The The Liabilities of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Nov 1, 2026 is 659.67 M CNY. In the previous year, The Liabilities was 781.52 M CNY — a change of -15.59% (lower).

Liabilities

659.67 MCNY

YoY

-15.59%

Last updated:

In 2025, Tibet Duo Rui Pharmaceutical Co's total liabilities amounted to 659.67 M CNY, a -15.59% difference from the 781.52 M CNY total liabilities in the previous year.

The Tibet Duo Rui Pharmaceutical Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
160.51 M CNY
Jan 1, 2019
144.14 M CNY
Jan 1, 2020
132.25 M CNY
Jan 1, 2021
62.79 M CNY
Jan 1, 2022
145.45 M CNY
Jan 1, 2023
250.59 M CNY
Jan 1, 2024
781.52 M CNY
Jan 1, 2025
659.67 M CNY
The Tibet Duo Rui Pharmaceutical Co Liabilities history
YEARLiabilitiesYoY
659.67 MCNY-15.59%
781.52 MCNY+211.87%
250.59 MCNY+72.28%
145.45 MCNY+131.65%
62.79 MCNY-52.52%
132.25 MCNY-8.25%
144.14 MCNY-10.19%
160.51 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Tibet Duo Rui Pharmaceutical Co's Liabilities

Tibet Duo Rui Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Tibet Duo Rui Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Tibet Duo Rui Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Tibet Duo Rui Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Tibet Duo Rui Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

The Liabilities of Tibet Duo Rui Pharmaceutical Co is 659.67 M CNY in 2025.

The Liabilities of Tibet Duo Rui Pharmaceutical Co changed from 781.52 M CNY to 659.67 M CNY, representing a -15.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Tibet Duo Rui Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Tibet Duo Rui Pharmaceutical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Tibet Duo Rui Pharmaceutical Co